American Association for Cancer Research

November 15 Cancer Research Highlights

PDF Version for Printing pdf4.gif

Selected Articles from the November 15, 2006 Issue

The articles referenced in this Highlights section will be available online in HTML and PDF formats to all interested users at no charge until the next issue of Cancer Research is published. Click on the article title to view the complete article.

View the Table of Contents for the November 15 issue of Cancer Research.


Epigenetic Silencing of the HOXA Gene Cluster in Breast Cancer 

Novak et al.
Page 10664

Novak et al. November 15 Cancer ResearchEpigenomic scanning and gene expression profiling were used in this study to define a contiguous region of aberrant methylation and epigenetic silencing encompassing the HOXA gene cluster in human breast cancer. Transcriptional repression occurred within a region of 100 kb in this gene cluster and did not extend to genes located upstream or downstream of the cluster. Novak et al. present evidence that this type of genomic lesion is reversible by a DNA
demethylating agent. Together their findings suggest a new type of genomic lesion in cancer that they term an "epigenetic microdeletion," which functionally resembles a genetic deletion, but is defined by epigenetic silencing along a contiguous chromosomal region. 

 


p53 Represses Stromal SDF-1 Production 

Moskovits et al.
Page 10671

Moskovits et al. November 15 Cancer ResearchTumor suppressor activities of p53 within cancer cells have been extensively investigated. Moskovits et al. now report that p53 also acts on fibroblasts in tumor stroma by repressing expression and secretion of SDF-1, a chemokine that acts in the CXCR4 pathway to stimulate the migration and invasiveness of tumor cells. Given the well documented contribution of SDF-1 to tumor progression and metastasis, these findings suggest that p53-activating drugs may exert anticancer effects within stromal fibroblasts in tumors as well as on the tumor cells themselves. 

 

 


LKB1 Is Recruited to p21 Promoter by p53 

Zeng and Berger
Page 10701

Mutation of the tumor suppressor gene LKB1, which encodes an evolutionarily conserved serine/threonine kinase, is associated with Peutz-Jeghers syndrome and elevated cancer susceptibility. Previous studies have shown that LKB1 can physically bind to p53 and stabilize it in cells. In this study, Zeng and Berger extend these findings by showing that transcriptional activation of the p53 target gene p21/WAF1, a crucial cell-cycle regulator, is associated with p53-dependent recruitment of LKB1 to the promoter of the p21/WAF1 gene. Notably, genetic fusion of LKB1 to a p53 mutant lacking its activation domain was capable of fully activating transcription of the p21/WAF1 gene. The results indicate that LKB1 has a direct and sufficient role in the ability of p53 to activate this important target gene. 


Eph Receptors Show Prognostic Value 

Castellano et al.      Page 10709

Liu et al.                  Page 10815

Castellano et al. November 15 Cancer ResearchEph receptors can mediate cell repulsion and migration depending on cell-cell interaction. Members of this class of cell surface receptors are often overexpressed in tumors where they may function in an altered manner. Two articles in this issue of the journal report the possible prognostic value of Eph receptors EphA2 in glioma and EphB4 in ovarian cancers, the overexpression of which are associated with poor clinical outcomes. These findings underscore emerging interest in understanding Eph receptor function in cancer.